Major Shareholder Announcement Nov 9, 2023 09:14AM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2023 Oct 17, 2023 06:22AM
Genmab Updates 2023 Financial Guidance Jul 27, 2023 06:01PM
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2023 Jul 20, 2023 06:22AM
Genmab (GMAB) EPKINLY Approved by FDA as First and Only Bispecific Antibody to Treat Adults with R/R Diffuse Large B-cell Lymphoma May 19, 2023 12:34PM
View Older Stories

May 19, 2023 12:33PM EPKINLY™ (epcoritamab-bysp) Approved by U.S. Food and Drug Administration as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (D
Apr 24, 2023 04:39AM Genmab To File Appeal in Its Second Arbitration Under License Agreement with Janssen
Apr 20, 2023 07:45PM Genmab Announces Initial Resolution of Its Second Arbitration Under License Agreement with Janssen
Apr 18, 2023 06:25AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2023
Apr 17, 2023 02:00AM Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology
Mar 14, 2023 09:00AM Stalkerware Grows 239% Worldwide Over the Past Three Years
Mar 9, 2023 10:00AM Avast Introduces Avast One Platinum
Feb 23, 2023 09:00AM LifeLock Offers Up to $3 Million in Identity Theft Coverage and Expanded Social Media Monitoring and Lock and Freeze Center Features
Feb 22, 2023 11:13AM Genmab (GMAB) Announces Initiation of Share Buy-Back Program
Feb 22, 2023 11:12AM Genmab Announces Initiation of Share Buy-Back Program
Feb 22, 2023 11:01AM Genmab Publishes 2022 Annual Report
Feb 9, 2023 08:00AM Avast Threat Report: Consumers Plagued with Refund Fraud, Tech Support Scams and Adware
Jan 24, 2023 06:27AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022
Dec 21, 2022 08:16AM AARP Services Announces New and Enhanced Benefits and Programs for AARP Members
Dec 20, 2022 08:00AM The European Commission selected the EU Digital Identity Wallet Consortium for the EU Digital Identity Wallet Pilots
Nov 3, 2022 12:45PM Genmab Improves Its 2022 Financial Guidance
Oct 18, 2022 06:35AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022
Oct 5, 2022 03:56PM Major Shareholder Announcement
Aug 8, 2022 12:34PM Genmab A/S (GMAB) Improves FY22 Financial Guidance
Aug 8, 2022 12:33PM Genmab Improves Its 2022 Financial Guidance
Aug 2, 2022 02:46PM Major Shareholder Announcement
Jul 20, 2022 01:03PM Major Shareholder Announcement
Jul 19, 2022 06:33AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022
Jul 18, 2022 10:02AM Genmab (GMAB) Announces That AbbVie (ABBV) Will Submit MAA to EMA for Epcoritamab for the Treatment of R/R DLBCL
Jul 18, 2022 10:01AM Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-
Jul 11, 2022 11:28AM Major Shareholder Announcement
Jul 1, 2022 10:14AM Major Shareholder Announcement
Jun 30, 2022 02:25PM Genmab A/S (GMAB) to Submit BLA to FDA for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
Jun 30, 2022 02:24PM Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)
Jun 20, 2022 10:35AM Major Shareholder Announcement
Jun 9, 2022 05:17PM Genmab Commences New Arbitration Under License Agreement With Janssen
Jun 1, 2022 12:21PM Major Shareholder Announcement
Apr 19, 2022 06:29AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022
Apr 13, 2022 05:25PM Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Apr 7, 2022 07:44PM Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License Agreement
Feb 24, 2022 06:01AM Notice to Convene the Annual General Meeting of Genmab A/S
Feb 16, 2022 11:00AM Genmab Publishes 2021 Annual Report
Jan 25, 2022 06:30AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021
Jan 4, 2022 09:00AM Genmab and Synaffix Enter into License Agreement for ADC Technology
Nov 4, 2021 04:24PM Genmab Improves its 2021 Financial Guidance
Oct 19, 2021 06:37AM Genmab (GMAB) Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Oct 19, 2021 06:29AM Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021
Sep 21, 2021 02:22PM Capital Increase in Genmab as a Result of Employee Warrant Exercise
Sep 20, 2021 05:00PM Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Apr 9, 2021 04:00PM Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
Feb 10, 2021 04:05PM Genmab and Seagen Submit Tisotumab Vedotin Biologics License Application to the U.S. FDA for Patients with Recurrent or Metastatic Cervical Cancer
Sep 21, 2020 10:20AM Genmab and Seattle Genetics Present Data from Tisotumab Vedotin innovaTV 204 Pivotal Trial in Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2020
Jun 10, 2020 06:04AM Genmab (GMAB) and AbbVie (ABBV) Announce Broad Oncology Collaboration, Genmab to Receive Upfront Payment of $750M With Total Potential Milestones of Up to $3.15B
Jun 10, 2020 06:00AM Genmab and AbbVie Announce Broad Oncology Collaboration
Dec 19, 2019 10:19AM Genmab and CureVac Enter Strategic Partnership to Develop mRNA-based Antibody Therapeutics
View Older Stories